RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $45
RBC Cuts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Outperform Rating
Tandem Diabetes Care Analyst Ratings
Mizuho Securities Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $20
Hold Rating for Tandem Diabetes Care Amid Competitive and Macroeconomic Challenges
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $27
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $53
Barclays Remains a Buy on Tandem Diabetes Care (TNDM)
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Tandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation Opportunity
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $24
Tandem Diabetes Care Cut to Equal-Weight From Overweight by Morgan Stanley
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $22
Tandem Diabetes Care Cut to Neutral From Buy by Citigroup
Citi Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $24
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25